Videos
Allergy Ranks Highest Impact Factor in Allergy
We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.
The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.
On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.
Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.
In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.
Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!
Maria Torres
EAACI President
Articles
Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma
Gates, J., Haris, F., Cefaloni, F., et al. Allergy. First published:14 May 2025
Involvement of IL-13-Induced Dysregulation of BDNF-NTRK2 Pathway in Symptoms of Eosinophilic Esophagitis
Osonoi, K., Sawada, A., Maekawa, Y., et al. Allergy. First published: 13 May 2025
Comprehensive αβ T-Cell Receptor Repertoire Analysis Reveals a Unique CD8+ TCR Landscape in DOCK8-Deficient Patients
Bozkurt, C., Cildir, G., Aba, U., et al.Allergy. First published: 10 May 2025
Childhood Asthma and Allergy Are Related to Accelerated Epigenetic Aging
Leskien, M., Thiering, E., Yu, Z., et al. Allergy. First published: 10 May 2025
Association Between a History of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-Based Case–Control Study
Chen, Y.-W., Yen, T.-H., Kao, C.-M., et al. Allergy. First published: 10 May 2025
Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer
Vogi, V., Jukic, E., Gruber, R., et al. Allergy. First published: 10 May 2025
Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report
Mayorga, C., Fernandez-Santamaria, R., Çelik, G.E., et al. Allergy. First published: 07 May 2025
Exercise Recommendations and Practical Considerations for Asthma Management—An EAACI Position Paper
Price, O.J., Papadopoulos, N.G., Amérigo, D.A., et al.Allergy. First published: 06 May 2025
Unmasking Convergent Inflammatory and Oxidative Pathways in Asthma
Tourlakopoulos, K., Mavrovounis, G., Kontopoulou, L., et al. Allergy. First published: 06 May 2025
Anaphylaxis Induced by Goat's and Sheep's Milk: An Allergen That We Should Keep Under Surveillance
Pouessel, G., Vaia, E.-S., Chatain, C., et al. Allergy. First published: 06 May 2025
CAR-T Cell Therapy in Autoimmune Setting: A New Appealing Approach Extendable to Allergy?
Rossi, F., Fernandez Santamaria, R. and Castagnoli, R. Allergy. First published: 06 May 2025
Clinical Characteristics of Difficult-To-Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score
Tanaka, J., Oguma, T., Ishiguro, T., et al. Allergy. First published: 02 May 2025
On a Rainy Day, Placebo Is the Ideal Treatment for Your Hay Fever
Mösges, R. Allergy. First published: 02 May 2025
Amphiregulin Mediates Epithelial Cell–Eosinophil Interactions and Amplifies Inflammation in Chronic Rhinosinusitis With Nasal Polyps
Zhao, L., Zhang, S., Zhang, Y., et al. Allergy. First published: 02 May 2025
Possible In-Cabin Exposure to Cat Allergen: A 2025 Airline Survey on Live Animal Transport and a Review of Literature
Möhrenschlager, M., Brüggen, M.-C. and Schmid-Grendelmeier, P. Allergy. First published:30 April 2025
The Discrepancy Between Perceived and Proven Drug Hypersensitivity in a Well-Defined Cohort of Patients With Inborn Errors of Immunity
Bilgic-Eltan, S., Karakurt, T., Yuksel, R.G., et al.Allergy. First published:29 April 2025
The Severity of Pollen-Induced Allergic Rhinitis at 16 Years of Age: Data From the Population-Based BAMSE Birth Cohort
Lindqvist, M., Westman, M., Linneberg, A., et al. Allergy. First published:29 April 2025
Reply to Correspondence: Causal Associations Between Chronic Spontaneous Urticaria and Thyroid Function Indicators on Different Ethnic Groups: A Bidirectional Two-Sample Mendelian Randomization Analysis
Ji, J., Yao, Y., Deng, L., et al. Allergy. First published:29 April 2025
Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross-Reactivity and Reintroduction in Chinese Population
Wai, C.Y.Y., Leung, N.Y.H., Leung, A.S.Y., et al. Allergy. First published:24 April 2025
Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials
Hunter, H., Ue, K.L., Cornelius, V., et al. Allergy. First published: 23 April 2025
Asthma Alleviation by Ginsenoside Rb1 via Promotion of Treg Proliferation and Inflammatory T Cell Inhibition
Choi, S., Yoo, S.-A., Ji, K.-Y., et al. Allergy. First published:19 April 2025
Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma
Fricker, M., Harrington, J., Hiles, S.A. and Gibson, P.G. Allergy. First published:19 April 2025
Early-Life Quarantine Increases the Development of Infant Atopic Dermatitis: A Birth Cohort Study in China
Hu, Y., Zhao, J., Shen, Q., et al. Allergy. First published:19 April 2025
Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema
Riedl, M.A., Yarlas, A., Bordone, L., et al. Allergy. First published:19 April 2025
Differential DNA Methylation in Peripheral Blood Mononuclear Cells Reflects Asthma Control Status in Adults
An, J., Park, J., Do, A.R., et al. Allergy. First published:19 April 2025
Endothelin-1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells
Wong, L.-S., Yang, J.-L., Yen, Y.-T., et al. Allergy. First published:18 April 2025
Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An EAACI Position Paper
Klimek, L., Brough, H.A., Arasi, S., et al. Allergy. First published:17 April 2025
Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial
Holzmann, C., Karg, J., Reiger, M., et al. Allergy. First published:17 April 2025
Correspondence to “Omalizumab Reduces Anaphylactic Reactions and Allows Food Introduction in Food-Allergic in Children With Severe Asthma: An Observational Study”
Klain, A., Indolfi, C., Grella, C., et al. Allergy. First published:17 April 2025
Reply to Correspondence: The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
Agache, I., Adcock, I.M., Akdis, C.A., et al. Allergy. First published: 11 April 2025
Correspondence to ‘Interleukin-5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils’
McCrae, C., Jison, M.L. and Menzies-Gow, A. Allergy. First published: 10 April 2025
Association Between Occupational Exposure and Sinus Surgery Outcomes in Chronic Rhinosinusitis: A Prospective Study
Vansteelant, G., Dietz de Loos, D.A.E., Ronsmans, S.,et al. Allergy. First published: 10 April 2025
Faecalibacterium in the Gut Microbiota Predicts Tolerance Acquisition in Pediatric Hen's Egg Allergy
Akagawa, S., Tsuji, S., Nakai, Y., et al. Allergy. First published: 10 April 2025
Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE
Gharailoo, Z., Vogel, M., Engeroff, P. and Bachmann, M.F. Allergy. First published: 07 April 2025
Management of Patients With Allergic Diseases in the Era of Biologics
Lan, F., Akdis, C.A. and Zhang, L. Allergy. First published: 05 April 2025
Recombinant Hypoallergenic Cat Allergy Vaccines
Trifonova, D., Curin, M., Focke-Tejkl, M., et al. Allergy. First published: 03 April 2025
Flow Cytometry-Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Elst, J., Mertens, C., Van Houdt, M., van der Poorten, et al. Allergy. First published: 03 April 2025
TOP10-SCAR: A Global Pharmacovigilance Study on Medications Most Frequently Related to Severe Cutaneous Adverse Reactions
Cho, J., Jo, H., Park, J.,et al. Allergy. First published: April 2025
NLRC4 Regulates Th2 Differentiation in Mice With Allergic Airway Inflammation Induced by House Dust Mite
Pak, S.-W., Kim, W.-I., Lee, S.-J., et al. Allergy. First published: 02 April 2025
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
The beginning of the new year brings us a lot of new meetings and opportunities to meet and learn about the most relevant scientific advances in the field! During the first months, members of the Junior Member Assembly (JMA) have participated in the EAACI Immunology Winter School 2025 in Schamlding, Austria (January 29 - February 2). This traditional winter school is designed specifically for Junior Members (JMs), providing an ideal platform to showcase their research. The meeting brought together attendees from over 15 countries, and featured 6 keynote speakers, 19 JM oral presentations, 49 posters and 5 hands-on sessions. The strong JM participation and the scientific program provided a comprehensive learning and networking experience, facilitating knowledge sharing and professional development for all attendees.
In February, also two JMA representatives have the opportunity and the great responsibility to attend the 2025 AAAAI/WAO Joint Congress held in San Diego, USA, and represent there all EAACI JMs. The always fruitful collaboration with our sister societies brings to both Academies important improvements in the knowledge of the fields of Allergy and Clinical Immunology through the preparation of educational resources, manuscripts, and different activities and collaborations. During the meeting, we had interesting discussions with our “Fellow-in-Training” colleagues, attended different lectures, symposia and courses organized by them, and enjoyed them very much! In addition, we participated in different talks and meetings organized there by our Academy.
See you at the next EAACI meetings and at the EAACI 2025 Congress in Glasgow!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
